Search

Your search keyword '"Eder, Sandra"' showing total 22 results
Start Over Author "Eder, Sandra" Publication Year Range Last 3 years
22 results on '"Eder, Sandra"'

2. R‐ketorolac ameliorates cancer‐associated cachexia and prolongs survival of tumour‐bearing mice

Author

Chrysostomou, Sophia E., primary, Eder, Sandra, additional, Pototschnig, Isabella, additional, Mayer, Anna‐Lena, additional, Derler, Martina, additional, Mussbacher, Marion, additional, Schauer, Silvia, additional, Zhang, Dongxu, additional, Yan, Dongmei, additional, Liu, Gennie, additional, Hoefler, Gerald, additional, Weichhart, Thomas, additional, Vesely, Paul W., additional, Zhang, Lingbing, additional, and Schweiger, Martina, additional

Published
2024
Full Text
View/download PDF

15. Advanced lipodystrophy reverses fatty liver in mice lacking adipocyte hormone-sensitive lipase

Author

Pajed, Laura, Taschler, Ulrike, Tilp, Anna, Hofer, Peter, Kotzbeck, Petra, Kolleritsch, Stephanie, Radner, Franz P. W., Pototschnig, Isabella, Wagner, Carina, Schratter, Margarita, Eder, Sandra, Huetter, Sabrina, Schreiber, Renate, Haemmerle, Guenter, Eichmann, Thomas O., Schweiger, Martina, Hoefler, Gerald, Kershaw, Erin E., Lass, Achim, and Schoiswohl, Gabriele

Published
2021
Full Text
View/download PDF

16. Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Kornauth, Christoph, primary, Pemovska, Tea, primary, Vladimer, Gregory I., primary, Bayer, Günther, primary, Bergmann, Michael, primary, Eder, Sandra, primary, Eichner, Ruth, primary, Erl, Martin, primary, Esterbauer, Harald, primary, Exner, Ruth, primary, Felsleitner-Hauer, Verena, primary, Forte, Maurizio, primary, Gaiger, Alexander, primary, Geissler, Klaus, primary, Greinix, Hildegard T., primary, Gstöttner, Wolfgang, primary, Hacker, Marcus, primary, Hartmann, Bernd Lorenz, primary, Hauswirth, Alexander W., primary, Heinemann, Tim, primary, Heintel, Daniel, primary, Hoda, Mir Alireza, primary, Hopfinger, Georg, primary, Jaeger, Ulrich, primary, Kazianka, Lukas, primary, Kenner, Lukas, primary, Kiesewetter, Barbara, primary, Krall, Nikolaus, primary, Krajnik, Gerhard, primary, Kubicek, Stefan, primary, Le, Trang, primary, Lubowitzki, Simone, primary, Mayerhoefer, Marius E., primary, Menschel, Elisabeth, primary, Merkel, Olaf, primary, Miura, Katsuhiro, primary, Müllauer, Leonhard, primary, Neumeister, Peter, primary, Noesslinger, Thomas, primary, Ocko, Katharina, primary, Öhler, Leopold, primary, Panny, Michael, primary, Pichler, Alexander, primary, Porpaczy, Edit, primary, Prager, Gerald W., primary, Raderer, Markus, primary, Ristl, Robin, primary, Ruckser, Reinhard, primary, Salamon, Julius, primary, Schiefer, Ana-Iris, primary, Schmolke, Ann-Sofie, primary, Schwarzinger, Ilse, primary, Selzer, Edgar, primary, Sillaber, Christian, primary, Skrabs, Cathrin, primary, Sperr, Wolfgang R., primary, Srndic, Ismet, primary, Thalhammer, Renate, primary, Valent, Peter, primary, van der Kouwe, Emiel, primary, Vanura, Katrina, primary, Vogt, Stefan, primary, Waldstein, Cora, primary, Wolf, Dominik, primary, Zielinski, Christoph C., primary, Zojer, Niklas, primary, Simonitsch-Klupp, Ingrid, primary, Superti-Furga, Giulio, primary, Snijder, Berend, primary, and Staber, Philipp B., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Kornauth, Christoph, primary, Pemovska, Tea, primary, Vladimer, Gregory I., primary, Bayer, Günther, primary, Bergmann, Michael, primary, Eder, Sandra, primary, Eichner, Ruth, primary, Erl, Martin, primary, Esterbauer, Harald, primary, Exner, Ruth, primary, Felsleitner-Hauer, Verena, primary, Forte, Maurizio, primary, Gaiger, Alexander, primary, Geissler, Klaus, primary, Greinix, Hildegard T., primary, Gstöttner, Wolfgang, primary, Hacker, Marcus, primary, Hartmann, Bernd Lorenz, primary, Hauswirth, Alexander W., primary, Heinemann, Tim, primary, Heintel, Daniel, primary, Hoda, Mir Alireza, primary, Hopfinger, Georg, primary, Jaeger, Ulrich, primary, Kazianka, Lukas, primary, Kenner, Lukas, primary, Kiesewetter, Barbara, primary, Krall, Nikolaus, primary, Krajnik, Gerhard, primary, Kubicek, Stefan, primary, Le, Trang, primary, Lubowitzki, Simone, primary, Mayerhoefer, Marius E., primary, Menschel, Elisabeth, primary, Merkel, Olaf, primary, Miura, Katsuhiro, primary, Müllauer, Leonhard, primary, Neumeister, Peter, primary, Noesslinger, Thomas, primary, Ocko, Katharina, primary, Öhler, Leopold, primary, Panny, Michael, primary, Pichler, Alexander, primary, Porpaczy, Edit, primary, Prager, Gerald W., primary, Raderer, Markus, primary, Ristl, Robin, primary, Ruckser, Reinhard, primary, Salamon, Julius, primary, Schiefer, Ana-Iris, primary, Schmolke, Ann-Sofie, primary, Schwarzinger, Ilse, primary, Selzer, Edgar, primary, Sillaber, Christian, primary, Skrabs, Cathrin, primary, Sperr, Wolfgang R., primary, Srndic, Ismet, primary, Thalhammer, Renate, primary, Valent, Peter, primary, van der Kouwe, Emiel, primary, Vanura, Katrina, primary, Vogt, Stefan, primary, Waldstein, Cora, primary, Wolf, Dominik, primary, Zielinski, Christoph C., primary, Zojer, Niklas, primary, Simonitsch-Klupp, Ingrid, primary, Superti-Furga, Giulio, primary, Snijder, Berend, primary, and Staber, Philipp B., primary

Published
2023
Full Text
View/download PDF

20. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Author

Kornauth, Christoph, primary, Pemovska, Tea, additional, Vladimer, Gregory I., additional, Bayer, Günther, additional, Bergmann, Michael, additional, Eder, Sandra, additional, Eichner, Ruth, additional, Erl, Martin, additional, Esterbauer, Harald, additional, Exner, Ruth, additional, Felsleitner-Hauer, Verena, additional, Forte, Maurizio, additional, Gaiger, Alexander, additional, Geissler, Klaus, additional, Greinix, Hildegard T., additional, Gstöttner, Wolfgang, additional, Hacker, Marcus, additional, Hartmann, Bernd Lorenz, additional, Hauswirth, Alexander W., additional, Heinemann, Tim, additional, Heintel, Daniel, additional, Hoda, Mir Alireza, additional, Hopfinger, Georg, additional, Jaeger, Ulrich, additional, Kazianka, Lukas, additional, Kenner, Lukas, additional, Kiesewetter, Barbara, additional, Krall, Nikolaus, additional, Krajnik, Gerhard, additional, Kubicek, Stefan, additional, Le, Trang, additional, Lubowitzki, Simone, additional, Mayerhoefer, Marius E., additional, Menschel, Elisabeth, additional, Merkel, Olaf, additional, Miura, Katsuhiro, additional, Müllauer, Leonhard, additional, Neumeister, Peter, additional, Noesslinger, Thomas, additional, Ocko, Katharina, additional, Öhler, Leopold, additional, Panny, Michael, additional, Pichler, Alexander, additional, Porpaczy, Edit, additional, Prager, Gerald W., additional, Raderer, Markus, additional, Ristl, Robin, additional, Ruckser, Reinhard, additional, Salamon, Julius, additional, Schiefer, Ana-Iris, additional, Schmolke, Ann-Sofie, additional, Schwarzinger, Ilse, additional, Selzer, Edgar, additional, Sillaber, Christian, additional, Skrabs, Cathrin, additional, Sperr, Wolfgang R., additional, Srndic, Ismet, additional, Thalhammer, Renate, additional, Valent, Peter, additional, van der Kouwe, Emiel, additional, Vanura, Katrina, additional, Vogt, Stefan, additional, Waldstein, Cora, additional, Wolf, Dominik, additional, Zielinski, Christoph C., additional, Zojer, Niklas, additional, Simonitsch-Klupp, Ingrid, additional, Superti-Furga, Giulio, additional, Snijder, Berend, additional, and Staber, Philipp B., additional

Published
2021
Full Text
View/download PDF

22. Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.

Author

Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, and Staber PB

Subjects
Adult, Aged, Aged, 80 and over, Austria, Cohort Studies, Female, Hematologic Neoplasms mortality, Humans, Male, Middle Aged, Molecular Targeted Therapy, Precision Medicine, Progression-Free Survival, Young Adult, Hematologic Neoplasms drug therapy
Abstract

Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of patients with cancer. A promising method may be drug profiling of patient biopsy specimens with single-cell resolution to directly quantify drug effects. We prospectively tested an image-based single-cell functional precision medicine (scFPM) approach to guide treatments in 143 patients with advanced aggressive hematologic cancers. Fifty-six patients (39%) were treated according to scFPM results. At a median follow-up of 23.9 months, 30 patients (54%) demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared with their previous therapy. Twelve patients (40% of responders) experienced exceptional responses lasting three times longer than expected for their respective disease. We conclude that therapy matching by scFPM is clinically feasible and effective in advanced aggressive hematologic cancers. SIGNIFICANCE: This is the first precision medicine trial using a functional assay to instruct n-of-one therapies in oncology. It illustrates that for patients lacking standard therapies, high-content assay-based scFPM can have a significant value in clinical therapy guidance based on functional dependencies of each patient's cancer. See related commentary by Letai, p. 290 . This article is highlighted in the In This Issue feature, p. 275 ., (©2021 The Authors; Published by the American Association for Cancer Research.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results